Table 2.
Factor | Total (n = 147) | Treatment response | 30-day outcome | ||||
---|---|---|---|---|---|---|---|
Failure (n = 79) |
Success (n = 68) |
P value | Died | Survived | P value | ||
Resistance to | |||||||
Daptomycin (%) | 11 (7.48) | 8 (10.1) | 3 (4.41) | 0.1892 | 4 (8.51) | 7 (7.00) | 0.7448 |
Fusidic acid (%) | 11 (7.48) | 6 (7.59) | 5 (7.35) | 0.9577 | 3 (6.38) | 8 (8.00) | 1.000* |
Linezolid (%) | 0 (0) | 0 (0) | 0 (0) | … | 0 (0) | 0 (0) | … |
TMP-SXT (%) | 108 (73.5) | 62 (78.5) | 46 (67.7) | 0.1380 | 37 (78.7) | 71 (71.0) | 0.3226 |
Teicoplanin (%) | 2 (1.36) | 0 (0) | 2 (2.94) | 0.2123 | 0 (0) | 2 (2.00) | 1.000* |
Tigecycline (%) | 5 (3.40) | 4 (5.06) | 1 (1.47) | 0.3735 | 3 (6.38) | 2 (2.00) | 0.3276 |
Rifampin (%) | 38 (25.9) | 23 (29.1) | 15 (22.1) | 0.3300 | 16 (34.0) | 22 (22.0) | 0.1199 |
hVISA phenotype | 55 (37.4) | 38 (48.1) | 17 (25.0) | 0.0039 | 24 (51.1) | 31 (31.0) | 0.0191 |
Delta-hemolysis | 106 (72.1) | 55 (69.6) | 51 (75.0) | 0.4683 | 31 (66.0) | 75 (75.0) | 0.2542 |
Agr type | 0.2533 | 0.6534 | |||||
Type 1 | 123 (83.7) | 69 (87.3) | 54 (79.4) | 41 (87.2) | 82 (82.0) | ||
Type 2 | 21 (14.3) | 10 (12.7) | 11 (16.2) | 6 (12.8) | 15 (15.0) | ||
Type 4 | 2 (1.36) | 0 (0) | 2 (2.94) | 0 (0) | 2 (2.00) | ||
untypable | 1 (0.68) | 0 (0) | 1 (2.94) | 0 (0) | 1 (1.00) | ||
SCCmec type | 0.0072 | 0.2801 | |||||
II | 16 (10.9) | 10 (12.7) | 6 (8.82) | 6 (12.8) | 10 (10.0) | ||
III | 105 (71.4) | 63 (79.8) | 42 (61.8) | 37 (78.7) | 68 (68.0) | ||
IV | 19 (12.9) | 6 (7.59) | 13 (19.1) | 4 (8.51) | 15 (15.0) | ||
V | 4 (2.72) | 0 (0) | 4 (5.88) | 0 (0) | 4 (4.00) | ||
untypable | 3 (2.04) | 0 (0) | 3 (4.41) | 0 (0) | 3 (3.00) | ||
PVL genes | 1 (0.68) | 0 (0) | 1 (1.47) | 0.4626* | 0 (0) | 1 (1.00) | 1.000* |
*Fisher’s exact test.